Adipendenza ™ | Treatment for Substance Abuse Disorder
People who suffer from substance abuse disorder face many challenges including having difficult emotions, cravings, relationship problems, financial problems, loneliness, boredom, stress, and poor mental health. While nearly everyone may experience some of these challenges, substance abuse disorder patients have a more difficult time coping with these symptoms and are more likely to relapse. As effective as medications can be in conjunction with professional counseling, cravings and relapse are often experienced when recovering from substance abuse.
Synergistic Therapeutics offers Adipendenza to treat substance abuse disorder and opioid dependency. The medication has also been effective for treating anxiety, depression (MDD & TRD), postpartum depression, post- traumatic stress disorder (PTSD), bipolar disorder, and other indications of depression.
Medication will primarily create patient severance from the abused substance.
Medication-Assisted Treatment (MAT) combines pharmacological treatment with behavioral treatment tailored to the patient's needs.
MAT should effectively reduce cravings and decrease the substance disorder.
MAT has also been shown to increase patient’s survival rates, increase treatment retention rates, decrease criminal activity related to opioid use and other drug use and increase the patients ability to gain or maintain employment.
Formulation is enhanced with a solution that should sever the patient from the abused substance.
Formulation includes elements that will quickly resolve a depressive mood or anxiety and depression. The formulation also will provide relief from acute and neuropathic pain issues.
Unlike other medications that treat substance disorder, the elements of our medication will rapidly sever the patient from the abused substance. The medication consists of a component utilized for the rapid resolution for depression and major depressive disorder/treatment resistant disorder, which enhances the efficacy.
Patent Status (USPTO):